CathVision

16 articles about CathVision

• CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

  12/12/2023

  CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software.

• CathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac Ablation

  8/15/2023

  CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA clearance and commercial availability of the PVI AnalyzerTM and Signal ComplexityTM algorithms.

• CathVision Secures $9 Million in Funding to Accelerate Adoption of ECGenius System & CARDIALYTICS AI-Suite

  7/18/2023

  CathVision, a medical technology company developing innovative electrophysiology solutions designed to support clinical decision making in the EP lab, today announced its most recent financing round of $9 million from investors.

• CathVision's ECGenius System to be Featured at HRS 2023 Rhythm Theater Symposium and Scientific Presentations

  5/15/2023

  CathVision today announced an extensive slate of educational opportunities and scientific sessions at this year's Heart Rhythm conference demonstrating the significant impact of the ECGenius™ System and potential benefits of AI-based analytics.

• Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst

  4/17/2023

  CathVision announced initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity™ algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.1 The first patient has been enrolled.

• ECGenius System to be Featured at AF Symposium 2023

  2/1/2023

  CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the ECGenius™ System will be featured in a Spotlight Session at the 28th Annual International AF Symposium in Boston, February 2-4, highlighting emerging technologies in cardiac electrophysiology.

• CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

  11/2/2022

  CathVision, a medical technology company developing innovative electrophysiology solutions to enhance clinical decision-making in the EP lab, today announced the investigation of the Signal Complexity™ algorithm designed to visualize and quantify atrial fibrillation (AF) complexity parameters in patients with persistent AF.

• CathVision Announces Close Of $7.2 Million Financing Round

  8/17/2022

  CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the company has secured $7.2 million in funding from existing investors.

• CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology

  5/4/2022

  CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the ECGenius EP Recording System.

• CathVision Announces Completion of Patient Enrollment at First U.S. Clinical Trial Evaluating High-Fidelity, Low-Noise EP Recording Technology

  4/26/2022

  CathVision, today announced the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center.

• CathVision adds US profile to its Board of Directors

  3/16/2021

  CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, is announcing a change to its Board of Directors.

• CathVision clinical results to be presented at the AF Symposium

  1/29/2021

  CathVision ApS, a medical device company developing a novel cardiac electrophysiology system and artificial intelligence platform to guide ablation therapy for heart rhythm disorders, is featured at the 26th annual international AF Symposium, held online January 29-31st.

• Cathvision Completes New Investment Round of a Total 13M Euro

  5/19/2020

  CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total 13M euro.

• CathVision Expand Board of Directors

  5/27/2019

  CathVision ApS announced the addition of two industry leaders to its Board of Directors.

• CathVision Receives ISO 13485:2016 Certification

  10/2/2018

  CathVision ApS announced today that the company received ISO 13485:2016 certification for Medical Device and Quality Management Systems from Lloyd's Register.

• CathVision Raises Venture Funding to Market New EP Recording System

  7/7/2017